pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

COMPANY OVERVIEW

ADC Therapeutics is focused on the development of proprietary Antibody Drug Conjugates (ADCs) for the treatment of both solid and hematological cancers.

LOCATION

  • Epalinges, , Switzerland

  • London, , UK

  • Murray Hill, NJ, USA

  • San Mateo, CA, USA

    • THERAPEUTIC AREAS

  • Oncology

    • WEBSITE

    https://adctherapeutics.com/

    CAREER WEBSITE

    None

    SOCIAL MEDIA

    INVESTORS

    astrazeneca auven-therapeutics redmile the-wild-family-office

    PRESS RELEASES


    Aug 26, 2019

    ADC Therapeutics and Freenome Enter Biomarker Development Collaboration


    Aug 6, 2019

    ADC Therapeutics and SOPHiA GENETICS Partner for Biomarker Discovery in Pivotal Phase II Clinical Trial


    Apr 25, 2018

    ADC Therapeutics Announces the Termination of its ADCT-502 Program Targeting HER2 Expressing Solid Tumors


    Apr 11, 2018

    ADC Therapeutics to Present Two New Investigational Antibody-Drug Conjugates at the American Association for Cancer Research (AACR) Annual Meeting


    Dec 11, 2017

    ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-301


    For More Press Releases
    Google Analytics Alternative